Pancreatic ductal adenocarcinoma (PDAC) is predicted to become the second leading cause of cancer-related deaths in the United States by 2020, due in part to innate resistance to widely used chemotherapeutic agents and limited knowledge about key molecular factors that drive tumor aggression. We previously reported a novel negative prognostic biomarker, keratin 17 (K17), whose overexpression in cancer results in shortened patient survival. In this study, we aimed to determine the predictive value of K17 and explore the therapeutic vulnerability in K17-expressing PDAC, using an unbiased high-throughput drug screen. Patient-derived data analysis showed that K17 expression correlates with resistance to Gemcitabine (Gem). In multiple in vitro models of PDAC, spanning human and murine PDAC cells, we determined that the expression of K17 results in a more than twofold increase in resistance to Gem and 5-fluorouracil, key components of current standard-of-care chemotherapeutic regimens. Furthermore, through an unbiased drug screen, we discovered that Podophyllotoxin (PPT), a microtubule inhibitor, showed at least two-fold higher sensitivity in K17expressing compared to K17-negative PDAC cells. In the clinic, another microtubule inhibitor, Paclitaxel (PTX), is used in combination with Gem as a first line chemotherapeutic regimen for pancreatic, breast, lung, and ovarian cancer. Surprisingly, we found that when combined with Gem, PPT but not PTX, was synergistic in inhibiting the viability of K17-expressing PDAC cells. This provides evidence that PPT or its derivatives could potentially be combined with Gem to enhance treatment efficacy for the approximately 50% of PDACs that express high levels of K17. In summary, we reported that K17 is a novel target for developing a biomarker-based personalized treatment for PDAC.
Introduction
Pancreatic Ductal Adenocarcinoma (PDAC) is one of the deadliest types of cancer, with a 5year survival rate at only 7%1. This extremely poor prognosis is due in part to the lack of effective screening strategies to detect PDAC at early stages2, and to the inherent resistance of these tumors to currently available first-line chemotherapeutic agents3,4.
The majority of patients are diagnosed at late metastatic or advanced stages and as a result, only 10-15% of PDACs are candidates for surgical resection5. With or without surgery, patients are subjected to chemotherapy where Gemcitabine (Gem) was the baseline treatment for more than a decade and is still employed6. Currently, Gem, combined with paclitaxel albumin-bound nanoparticles (nab-PTX, Abraxane)7 and the FOLFIRINOX regimen (5-Fluorouracil , leucovorin, irinotecan, and oxaliplatin)8 are two standard-of-care therapies that have been found to improve the survival rates compared to the use of Gem alone9. However, despite this improvement, PDACs usually show only weak response to all current treatment regimens10. Therefore, exploring biomarker-driven novel therapies is a critical priority for improving therapeutic outcomes for PDAC patients.
To this end, it was reported and recently validated in several cohorts that PDAC is composed of two molecular subtypes, based on distinct gene expression profiles that impact on patient survival11- 14. These differential gene expression signatures are now being used as biomarkers for molecular subtyping15-17, however, whether the proteins encoded by these genes cause resistance to treatment and if they could be exploited as therapeutic targets for PDAC remain unexplored.
We independently demonstrated that keratin 17 (K17), one signature gene overexpressed in the basal-like PDAC12, is an independent negative prognostic biomarker and is as accurate as molecular subtyping to predict PDAC patient survival15. However, it is still unknown if K17 is predictive for treatment response and if K17 expression in PDAC cells sensitizes them to specific and currently available small-molecule inhibitors. To address these questions, we evaluated K17 mRNA expression of PDACs from patients that received Gem treatment as standard-of-care versus no treatment. This led us to identify that K17 is a predictive marker of Gem response. In addition, a high-throughput small-compound screen uncovered a novel therapeutic vulnerability of tumors bearing K17 expression. Our findings support the conclusion that K17 could be a target for the development of a novel, and potentially more effective biomarker-based personalized therapy for PDAC.
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Test Well = Cells + compound, Data Wells = All test wells, High Control = media only plus DMSO. A mathematical algorithm was used to determine active compounds (Hits) . Two values were calculated:
(1) the average percent response of all compounds, and (2) three times their standard deviation. The sum of these two values was used as a cutoff parameter, i.e. any compound that exhibited greater percent activation than the cutoff parameter was declared active as a hit (p<0.0001).
Cell viability and proliferation assays
Cell viability was examined using the CellTiter-Glo® Luminescent Cell Viability Assay (Promega), or the WST-1 Cell Proliferation Reagent (Sigma-Aldrich). Cells were plated in 96 well plate at 6 × 104 cells/well and incubated overnight, drugs were added with 10-point dose-response titrations in triplicate (0.5 -20000 nM) or at indicated concentration for 48 hours. For WST-1 colorimetric assay, 10 uL of WST-1 was added per well, and the plate was incubated for 30 minutes and gently shaken. The absorbance was measured using a microplate (ELISA) reader at 450 nm and the reference at 630 nm. To measure cell proliferation, cells were plated at 4 × 104 cells/well in 96-well plates and the relative proliferation index was measured by WST-1 assay at each time point.
Flow cytometric cell cycle analysis
The percent cells at each cell cycle phase was assessed through propidium iodide (PI; Sigma-Aldrich) nuclear staining. Cells were seeded at 3 × 105 cells/dish in 60 mm dishes for 24 hours, and were exposed to DMSO or PPT treatment at 20 nM for 48 hours. After treatments, cells were harvested and stained with PI in Kreshan modified buffer for 30 minutes. The percent cells at each cell cycle phase and apoptosis were measured by flow cytometry (BD Biosciences) and data were analyzed by ModFit LTTM (Verity Software House).
Statistics
The half maximal inhibitory concentration (IC50) of single drug treatment was determined by GraphPad Prism 7 (Graph Pad Software) or Symyx software (Symyx Technologies Inc.). The specificity of compounds was calculated by: = 50 50 , and defined as following: less than 0.5: low, between 0.5 to 2: medium, greater than 2: high. The combination index (CI) and IC50 6 for drug combinations were calculated using CompuSyn software (www.combosyn.com), according to the Chou-Talalay model, one of the most widely used methods for detecting and quantifying synergistic interactions between drugs23. CI<0.9 indicates a synergistic effect. CI=0.9-1.2 indicates an additive effect. CI>1.2 indicates an antagonistic effect. The statistical significance between two groups was determined using Student's t-test. Data were expressed as means ± standard deviation (SD) or standard error mean (SEM), and *p<0.05, **p<0.01, ***p<0.001 were considered significant. 7 
Results

K17 is a novel predictive biomarker of Gemcitabine chemotherapy in PDAC
We previously reported that K17 is a prognostic biomarker for PDAC patients. Here, we set out to test if K17 could be a predictive biomarker in PDAC. Using APGI patient data13, we first defined K17 status in PDACs by analyzing K17 mRNA expression and applying the previously established cut-off15 to categorize high-and low-K17 cases (K17 mRNA Z-scores ranged from -0.66 to 11.17). High-K17 cases were defined as those in the top 24th percentile of K17 expression, while low-K17 cases were the lowest 76th percentile (Fig. 1A) . This 76th threshold, which provides maximal stratification of survival differences based on K17 mRNA expression, was trained and subsequently adjusted previously. We first validated the prognostic value of K17. Patients with high-K17 PDACs had a shorter median survival (14 months) than patients with low-K17 PDACs (23 months) (HR = 1.8, log-rank P = 0.0334) ( Fig. 1B) . Furthermore, the prognostic value of K17 mRNA status was independent of pathological stage ( Fig 1C) .
To determine if K17 expression predicts response to treatment with Gemcitabine (Gem), we analyzed the survival of patients harboring high or low K17-expressing tumors, comparing treatment of Gem alone (adjuvant Gem) or no treatment using the APGI data. The low-K17 group treated with adjuvant Gem had a median survival of 32 months, which was significantly longer than the no treatment group, with a median survival of 9 months (HR = 0.34, log-rank P = 0.0002) ( Fig. 1D ). In contrast, the high-K17 PDACs did not show differences in the median survival between adjuvant Gem and no treatment groups (HR = 0.95, log-rank P = 0.9167) ( Fig. 1E ). This shows that the low-K17 group responded to Gem treatment but high-K17 group did not show any treatment response, suggesting that there was a qualitative predictive interaction according to Ballman et al18. Thus, beyond its role as a prognostic biomarker for PDAC, K17 is predictive for the response to Gem.
K17 actively drives chemoresistance to first-line therapeutic agents
Given an association between K17 expression and resistance to Gem, we set out to identify whether K17 expression actively promotes resistance to Gem and another key chemotherapeutic agent 5-Fluorouracil (5-FU), which are major components for the two first-line chemotherapies. To test this, we first generated a K17 loss-of-function (LOF) human cell line model, to assess the response to Gem and 5-FU. Using CRISPR-Cas9 technology, we knocked out endogenous expression of K17 from L3.6 human PDAC cell line ( Fig. 2A-B ). Isogenic cells with and without expression of K17 were treated with Gem or 5-FU and the IC50 was determined. We found that K17expressing cells showed significantly higher IC50 values of Gem ( We further validated these results in K17 gain-of-function (GOF) cell line models. Human PDAC cell line MIA PaCa-2 ( Fig. 2E -F) and murine KrasG12D, p53R172H pancreatic cancer cells (KPC Fig. 2G -H), which express low level of K17, were stably transduced to express K17 as K17 GOF cell line models. As proof of principle, K17-expressing cells showed significantly higher IC50 values compared to non-K17-expressing cells after treated with Gem ( Fig. 2I , MIA PaCa-2: 10-fold, KPC: 5fold) and 5-FU ( Fig. 2J , MIA PaCa-2: 3-fold, KPC: 7-fold). Importantly, we did not detect any large difference in proliferation rates ( Fig. 2N -P) or cell-cycle progression ( Fig. 2K -M) between K17-positive and K17-negative cells in these three cell line models, suggesting that the differences in response to Gem and 5-FU are not related to differences in cell division. These findings indicate that K17 expression enhances the intrinsic resistance to chemotherapeutic agents in PDAC cells in a cell autonomous matter, suggesting that K17 could be used as a novel predictive biomarker in PDAC.
An unbiased high-throughput drug screen reveals compounds that specifically target K17expressing PDAC
Considering that K17 expression drives chemoresistance to first-line therapeutic agents and that there are currently no therapeutic agents to target this intermediate filament, we set out to screen for small molecules that preferentially impact K17-expressing PDAC cells, with the goal of identifying therapeutic vulnerabilities in these cells and enhancing their response to current standard-of-care treatment. 8 We performed an unbiased high-throughput screen in isogenic L3.6 cells with or without expression of K17, against compounds from the Library of Pharmacologically Active Compounds (LOPAC) to identify the most effective and specific agents against K17-expressing cells (Fig. 3A ). This primary screen yielded 24 active compounds (hits) that showed high response rates in L3.6 K17expressing cells (Table 1 ). After completion of the first screen with K17-expressing cells, we performed a counterscreen assay with isogenic counterpart L3.6 K17 KO cells, and it yielded 16 active hits ( Table 1 ). The hits from both the primary screen and counterscreen (p<0.0001) were then evaluated for overlap and grouped in three categories. 10 compounds were found to be selective for the K17-expressing cells, 14 compounds were found to equally target both K17-expressing and K17 KO cells, and 2 compounds were found to be selective for K17 KO cells ( Fig. 3B , Table 1 ).
The 10 identified compounds that show higher response rates in K17-expressing cells fell into two main categories: those that inhibit microtubule assembly (Vincristine sulfate, Podophyllotoxin [PPT] and Vinblastine sulfate salt) and those that inhibit phosphodiesterase activity (Zardaverine, Enoximone, Quazinone and Imazodan). In this LOPAC screen, three compounds, Zardaverine, Vincristine sulfate and PPT showed the highest response rates among the 10 candidate hits ( Fig. 3C and Table 1 ). To validate the candidates, we determined the IC50 values in L3.6 cell line model and compounds were further defined as having high, medium or low specificity for K17-expressing cells ( Fig. 3D) . By cross-referencing results from these assays to determine selectivity, we found that PPT is the compound with the highest degree of specificity for K17-expressing cells and also required the lowest concentration to inhibit cell viability.
PPT is known to block cell division by destabilizing microtubule activity through binding tubulin24. To confirm the specificity of PPT in inhibiting K17-expressing PDAC cells, we performed an independent validation in additional K17-manipulated cell line models using the WST-1 cell viability assay. In L3.6 ( Fig. 3E ), MIA PaCa-2, and KPC ( Fig. 3G ) cell line models, PPT consistently demonstrated at least two-fold differences in the IC50 values of K17-expressing cells versus non-K17-expressing cells. Therefore, less than half of the dosage of PPT is required to exert the same inhibitory effect in K17-positive cells, as compared to K17-negative cells.
In addition, under PPT treatment, K17-positive cells showed significantly increased apoptosis compared to K17-negative cells in L3.6 ( Fig. 3F ) and MIA PaCa-2 ( Fig. 3H ) cells. In KPCs, a significantly increased population of tetraploid cells at G2/M phase were detected ( Fig. 3I) , as a result of the mechanism of action of this drug24; however, the proportion of apoptotic cells was similar between K17 and EV cells ( Fig. 3H ). Compared with additional validation experiments of Zardaverine from the same category ( Fig. S1A and B ), however, PTT was the only compound that consistently targeted K17-expressing cells across all models. Thus, through multiple independent validations of several cell lines, we identified that PPT is selectively effective in targeting K17-expressing PDAC cells.
Lastly, in the category of compounds that show similar efficacy in both 17-expressing and K17 KO cells, Mitoxantrone was selected for further studies because it shares a similar mechanism of action to current standard-of-care chemotherapeutic agents (DNA synthesis inhibitor) for PDAC25. Validation experiments showed that Mitoxantrone had similar sensitivity in K17-expressing and non-K17-expressing cells in all three cell line models ( Fig. S1D-E ). In addition, Tyrophostin AG 879, the drug targeting the K17 KO cells with the highest average response was chosen for further studies ( Fig. S1H -J). We validated that this drug was much more sensitive in L3.6 K17 KO cells ( Fig. S1I ); however, it was highly resistant in MIA PaCa-2 and KPC cells ( Fig. S1J ), potentially due to phenotypic differences between cell line models or off-target effects. These verify results from the screen in L3.6 cell line model (Fig. S1C ), and suggests that validation experiments of a high-throughput drug screen are necessary to confirm the on-target effect.
In summary, using an unbiased high-throughput drug screen, we identified and validated PPT as a potential drug to target K17-expressing PDAC cells.
Targeting microtubule disassembly rather than microtubule assembly is a therapeutic vulnerability in K17-expressing pancreatic cancers
To evaluate whether PPT might enhance Gem-mediated cytotoxicity and determine if the combined effect is synergistic, additive or antagonistic, we measured cell viability by treating with 9 increasing doses of the combination of Gem and PPT at fixed ratios (1:1 in L3.6 cells and 37.5:1 in MIA PaCa-2 and KPC cells, based on their IC50 values of Gem and PPT, according to established protocols26). We found that K17-expressing cells had significantly lower cell viability under the same doses compared with non-K17-expressing cells ( Fig. S2A-C ). In addition, the IC50 of the combination of Gem and PPT was lower in K17-expressing cells compared to isogenic cells lacking K17 expression. We computed the combination index (CI)23 to determine the interaction of Gem and PPT in PDAC cells. Along with increasing effective doses from 50 to 97% of cell viability, the combination of Gem and PPT demonstrated a strongly synergistic interaction as shown by CI values lower than 0.9 in L3.6 K17-expressing cells, and there was an additive (effective dose at 50-75%) to antagonistic (effective dose at 90-97%) effect in L3.6 K17 KO cells (Fig. 4A ). In MIA PaCa-2 cell line model, cotreatment showed an additive (effective dose at 50%) to antagonistic effect (effective doses at 75-97%) in K17-expressing (K17) cells and an antagonistic effect in non-K17-expressing (EV) cells (Fig.  4B ). In KPC cells, a strongly synergistic effect was found in KPC K17 cells (CI<0.5) while an antagonistic effect was observed in KPC EV cells (Fig. 4C) . In summary, we demonstrated that PPT in combination with Gem was synergistic or additive in K17-expressing cells but that these drugs had antagonistic effects in non-K17-expressing cells.
Currently, Gem is combined with Paclitaxel (Taxol, PTX), a compound that stabilizes microtubules and protects it from disassembly27 as a standard-of-care therapeutic regimen for PDAC7. Given that we identified PPT, a compound that destabilizes microtubules24, to be synergistic when combined with Gem in K17-expressing PDACs, we set out to determine whether the synergistic effect of Gem in combination with a microtubule inhibitor depends on a specific mechanism of action of PPT and/or PTX. First, we tested the IC50 values of PTX and found that they were similar in K17-positive versus K17-negative cells in L3.6 and KPC cell lines ( Fig. S1F -G) and the IC50 was lower in K17 cells than in EV cells in MIA PaCa-2 cell line model ( Fig. S1G ). Second, we tested the combination of PTX and Gem, using the same experimental setup of testing PPT combined with Gem. We found no obvious differences in the dose-response curves of the combination in K17-positive and K17-negative cells ( Fig. S2D-F) . Surprisingly, we found that PTX and Gem tended to have antagonistic effects in K17-expressing cells across isogenic model systems ( Fig. 4D-F) , while it only showed synergistic effects in KPC cells lacking K17 expression ( Fig. 4F ).
Together, we found that K17 expression sensitizes cells to PPT in combination with Gem, however, these effects are adverse when Gem is combined with PTX in the same cells, suggesting that the mode of action of microtubule dynamic inhibitors may have a direct and/or indirect effect on K17 intermediate filament dynamic or function. Future studies, however, are needed to test this hypothesis.
DISCUSSION
Here, we identify that expression of K17 in PDACs correlates and causes resistance to Gem treatment, while it sensitizes cells to an FDA-approved compound that causes microtubule disassembly, identified by high-throughput screen and downstream validation assays. In addition, we found that the combination of Gem and this microtubule inhibitor synergizes to specifically target K17expressing PDACs. This study is important as it reports a biomarker-based novel combination therapy that can be further tested in pre-clinical and clinical settings to target the most lethal molecular subtype of pancreatic cancer.
The report of the PDAC molecular subtypes was a key milestone for the advancement in understanding this highly lethal disease, opening three crucial research areas: 1) Development of clinical tests to subtype patients at the time of diagnosis; 2) Selection of the best standard of care (Gem/nab-PTX or FOLFIRINOX) for each molecular subtype; and 3) Identification of targeted therapies, based on PDAC subtypes.
It is critically important to develop clinical tests to subtype PDAC patients at the time of diagnosis, to provide the most appropriate therapy. We recently reported that K17 mRNA , a hallmark biomarker of the most lethal molecular subtype of PDAC, is as accurate as molecular subtyping to identify the PDAC patient population with the worst prognosis15. Moreover, K17 protein, as detected by immunohistochemistry (IHC), provides better prognostic value than mRNA. Importantly, we have established a protocol for K17 IHC that can be used both in research laboratory and in clinical laboratory diagnostic settings. As the only reported basal-like gene that provides both prognostic and predictive values, further studies are required to validate K17's predictive value at the protein level using IHC.
To date, there are no predictive biomarkers to inform PDAC response to either Gem/nab-PTX or FOLFIRINOX regimens28,29, to enhance therapeutic efficacy, or to prevent adverse effects based on the molecular characteristics of the tumors. Based on our findings, K17 may be a candidate predictive biomarker for response to Gem/nab-PTX. Our data also suggests that K17 promotes resistance to 5-FU, a main agent in FOLFIRINOX. As such, it is important to determine if K17 is a predictive marker of FOLFIRINOX in PDAC. Importantly, the COMPASS trial findings show that basallike PDACs tended to be more resistant to the FOLFIRINOX chemotherapy17. To our knowledge, K17 is the only gene expressed in the most lethal basal-like subtype of PDAC that actively promotes chemoresistance to Gem and 5-FU and thus, may represent a potential clinical target for personalized treatment.
With the goal of identifying novel targeted therapies using existing FDA-approved compounds that can be repurposed and fast-tracked for the treatment of the patients with K17-expressing PDACs, we performed a high-throughput drug screen using the LOPAC assay. Although previous LOPAC screens had been applied to PDAC cell lines30, to date, these screens have not been evaluated in the context PDAC molecular subtypes and in combination with current chemotherapeutic agents. Through validation studies in three different K17 loss-and gain-of-function PDAC cell line models, we report that Podophyllotoxin (PPT) was consistently found to preferentially target K17-expressing cells. Our findings suggest that microtubule assembly inhibitors may be potentially effective drugs for treating K17-expressing PDACs. These observations are novel because the combination of PPT and Gem as a potential regimen for cancer therapy has not been previously reported. Furthermore, we also found that PPT was the most effective agent to target K17-expressing PDAC cells and that it synergizes in combination with Gem. Surprisingly, these effects were not recapitulated when combining Gem with PTX. This suggests that the current standard-of-care therapy may be replaced by a more effective and synergistic combination: Gem and PPT. Although beyond the scope of this study, future studies should address the mechanistic basis regarding how K17 expression sensitizes PDAC cells to PPT treatment.
Importantly, compared to other microtubule inhibitors from our LOPAC screen (such as PTX, Vincristine sulfate and Vinblastine sulfate salt), PPT showed the highest specificity in inhibiting K17expressing PDACs. In a previous study, PPT was shown to significantly inhibit the growth of lung tumor cells and using in vitro and in vivo models, was cytotoxic in several human cancer cell lines31- 34. Although PPT is currently only used for treatment of HPV-mediated cutaneous lesions, its semisynthetic compounds, Etoposide and Teniposide, are widely used for cancer therapy in the clinic. A phase II trial previously showed that Gem combined with Etoposide exhibited a response rate 11 similar to published trials using Gem-based chemotherapies35. Despite extensive interest in utilizing PPT and its derivates for cancer therapy, very few of these agents have reached clinical practice, in part due to toxicity and solubility36-38. More selective PPT derivatives based on modified structures may enhance effective responses in K17-expressing PDACs. Future studies of testing the specificity of Etoposide and Tenitoposide, alone and in combination with Gem in K17-expressing PDACs are needed.
In summary, we discovered a novel therapeutic vulnerability of K17-expressing PDACs and identified a compound that when combined with Gem, may enhance tumor response, compared to the current standard-of-care with Gem/nab-PTX.
Conclusions
The identification of biomarker-driven novel therapies is a critical priority for improving survival of PDAC patients. K17 is a novel target for development of a biomarker-based personalized treatment for the most aggressive form of PDAC. We demonstrated that beyond its predictive value, K17 drives chemoresistance to Gem and 5-FU. Through an unbiased drug screen, we discovered that PPT showed at least 2-fold higher sensitivity in K17-positive PDAC cells. Surprisingly, we found that small molecules that inhibits microtubule disassembly (PPT) rather than microtubule assembly (PTX) specifically targets K17 PDACs, uncovering a novel therapeutic vulnerability of the most aggressive molecular subtype of PDAC. These studies serve as scientific premise to further launch pre-clinical testing of this novel combination therapy that can guide optimal therapeutic management, which is driven by data related to the molecular composition and biomarker expression in PDACs.
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